Amy Argabright
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amy Argabright has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Angelo D'Alessandro
University of Colorado Anschutz Medical Campus
99 shared publications - Julie A. Reisz
Department of Biochemistry and Molecular Genetics, School of Medicine, University of Colorado Anschutz, Aurora, Colorado
96 shared publications - Andrew Goodspeed
University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado
94 shared publications - Benjamin G. Bitler
Department of OB/GYN, The University of Colorado Anschutz Medical Campus, Aurora, Colorado
94 shared publications - Jennifer K. Richer
University of Colorado Anschutz Medical Campus 1 Department of Pathology Aurora, Colorado
94 shared publications - Jessica L. Christenson
University of Colorado Anschutz Medical Campus 1 Department of Pathology Aurora, Colorado
94 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (4)
Selenium-associated BHMT2 and DMGDH loci connect one-carbon metabolism, selenoprotein biology, and red blood cell fragility
- 7 September 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (4)
Open AccessSelenium-associated BHMT2 and DMGDH loci connect one-carbon metabolism, selenoprotein biology, and red blood cell fragility
- Open Access
- 28 August 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (10)
Farnesoid X receptor activates STAT3 to promote fatty acid oxidation and suppress inflammatory macrophage responses in cholestasis
- 28 August 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (10)
Open AccessFarnesoid X receptor activates STAT3 to promote fatty acid oxidation and suppress inflammatory macrophage responses in cholestasis
- Top Cited PapersOpen Access
- 1 June 2026
- Published by American Society of Hematology in Blood
The red blood cell proteome and interactome identify a Band 3-BLVRB axis regulating hypoxic metabolic adaptation
Red blood cells (RBCs) are transcriptionally silent yet dynamically remodel metabolism in response to oxygen tension. Using ultra-pure human RBCs, we generated the deepest contamination-free proteome to date (3,775 proteins) and mapped the oxygen-dependent interactome. These datasets reveal an oxygen-responsive metabolon centered on the Band 3 (SLC4A1) N-terminus. We identify biliverdin reductase B (BLVRB) as a previously unrecognized Band 3 interactor that dissociates under hypoxia, coincident with increased Band 3-deoxyhemoglobin contacts. This reversible assembly functions as an oxygen-sensitive switch coordinating redox and glycolytic remodeling. Humanized mice lacking Band 3 N-terminal segments exhibit impaired oxygen-dependent regulation of BLVRB binding to band 3, impaired hypoxic activation of glycolysis, reduced 2,3-bisphosphoglycerate synthesis, and diminished exercise tolerance, demonstrating physiological relevance. Population-scale cis-pQTLs for SLC4A1 and BLVRB suggest functions beyond canonical heme catabolism. Mechanistically, biochemical analyses in vitro suggest that hemoglobin β (HBB), Band 3, and BLVRB can undergo S-nitrosation and may participate in trans-nitrosation reactions with the glycolytic enzyme GAPDH, whose modification at C152 inhibits enzymatic activity in vitro. Collectively, these findings define a Band 3-BLVRB axis that integrates oxygen-dependent protein interactions with thiol-based redox chemistry, providing a framework for understanding how an anucleate cell achieves metabolic adaptability through reversible protein-protein interactions and post-translational modification. These findings suggest that perturbation of the Band 3-BLVRB axis may influence oxygen delivery and metabolic flexibility during hypoxic stress, with potential relevance to high-altitude adaptation, exercise physiology, and cardiopulmonary disease.
- 1 June 2026
- Published by American Society of Hematology in Blood
Top Cited PapersOpen AccessThe red blood cell proteome and interactome identify a Band 3-BLVRB axis regulating hypoxic metabolic adaptation
Red blood cells (RBCs) are transcriptionally silent yet dynamically remodel metabolism in response to oxygen tension. Using ultra-pure human RBCs, we generated the deepest contamination-free proteome to date (3,775 proteins) and mapped the oxygen-dependent interactome. These datasets reveal an oxygen-responsive metabolon centered on the Band 3 (SLC4A1) N-terminus. We identify biliverdin reductase B (BLVRB) as a previously unrecognized Band 3 interactor that dissociates under hypoxia, coincident with increased Band 3-deoxyhemoglobin contacts. This reversible assembly functions as an oxygen-sensitive switch coordinating redox and glycolytic remodeling. Humanized mice lacking Band 3 N-terminal segments exhibit impaired oxygen-dependent regulation of BLVRB binding to band 3, impaired hypoxic activation of glycolysis, reduced 2,3-bisphosphoglycerate synthesis, and diminished exercise tolerance, demonstrating physiological relevance. Population-scale cis-pQTLs for SLC4A1 and BLVRB suggest functions beyond canonical heme catabolism. Mechanistically, biochemical analyses in vitro suggest that hemoglobin β (HBB), Band 3, and BLVRB can undergo S-nitrosation and may participate in trans-nitrosation reactions with the glycolytic enzyme GAPDH, whose modification at C152 inhibits enzymatic activity in vitro. Collectively, these findings define a Band 3-BLVRB axis that integrates oxygen-dependent protein interactions with thiol-based redox chemistry, providing a framework for understanding how an anucleate cell achieves metabolic adaptability through reversible protein-protein interactions and post-translational modification. These findings suggest that perturbation of the Band 3-BLVRB axis may influence oxygen delivery and metabolic flexibility during hypoxic stress, with potential relevance to high-altitude adaptation, exercise physiology, and cardiopulmonary disease.
- Open Access
- 25 May 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (3) , 567-582
Liver-directed lentiviral gene therapy confers durable hepatic and systemic amelioration of methylmalonic acidemia in mice
- 25 May 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (3) , 567-582
Open AccessLiver-directed lentiviral gene therapy confers durable hepatic and systemic amelioration of methylmalonic acidemia in mice
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Treatment of AT-0174, epacadostat or StemRegenin reduces invasion in SUM159PT cells.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Treatment of AT-0174, epacadostat or StemRegenin reduces invasion in SUM159PT cells.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Compound AT-0174 decreased secreted KYN in TDO2 overexpression (OE) cells.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Compound AT-0174 decreased secreted KYN in TDO2 overexpression (OE) cells.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Genetic knockdown or pharmacological inhibition of TDO2 or AhR decreased ZEB1 mRNA expression but increased while IDO1 compensated; KYN treatment increased ZEB1 expression.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Genetic knockdown or pharmacological inhibition of TDO2 or AhR decreased ZEB1 mRNA expression but increased while IDO1 compensated; KYN treatment increased ZEB1 expression.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Tryptophan catabolism to kynurenine was enhanced in cells surviving in the anchorage independent condition over time.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Tryptophan catabolism to kynurenine was enhanced in cells surviving in the anchorage independent condition over time.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Significant GSEA full list of Bulk RNA-seq for BT549 shTDO2-82 vs. shSCR control
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Significant GSEA full list of Bulk RNA-seq for BT549 shTDO2-82 vs. shSCR control
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Significant GSEA of Bulk RNA-seq for BT549 (under suspension condition) treated with AT-0174 vs. Vehicle
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Significant GSEA of Bulk RNA-seq for BT549 (under suspension condition) treated with AT-0174 vs. Vehicle